Publications

1. GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

   The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...

   Report | 24-02-2022

2. GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

   The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

   Report | 22-02-2022

3. GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

   The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...

   Report | 10-02-2022

4. Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

   The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

   Report | 25-01-2022

5. Package advice tucatinib (Tukysa®)

   The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...

   Report | 17-01-2022

6. Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia

   The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...

   Report | 17-01-2022

7. GVS advice on volanesorsen (Waylivra)

   The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

   Report | 10-01-2022

8. GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions

   The National Health Care Institute completed its assessment whether the further conditions of tezacaftor/ivacaftor (Symkevi®) and ...

   Report | 21-12-2021

9. Package advice on ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) for the treatment of inoperable malign pleural mesothelioma

   The National Health Care Insititute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...

   Report | 17-12-2021

10. Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

    The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...

    Report | 15-12-2021